Login / Signup

Structural basis for the inhibition of the SARS-CoV-2 main protease by the anti-HCV drug narlaprevir.

Yu BaiFei YeYong FengHanyi LiaoHao SongJianxun QiGeorge Fu GaoWenjie TanLifeng FuYi Shi
Published in: Signal transduction and targeted therapy (2021)
Keyphrases
  • structural basis
  • sars cov
  • hepatitis c virus
  • respiratory syndrome coronavirus
  • human immunodeficiency virus
  • adverse drug
  • emergency department
  • coronavirus disease
  • antiretroviral therapy